Search results
Your search for follwing guidelines returned no results
Showing 651 to 700 of 1116 results for following guidelines
Showing 651 to 700 of 1116 results for following guidelines
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)
Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
Cardiac contractility modulation device implantation for heart failure (IPG655)
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.
View recommendations for IPG655Show all sections
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)
NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)
Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Read biographies for all members of NICE's indicator advisory committee.
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.